(0.02%) 5 071.63 points
(-0.11%) 38 461 points
(0.10%) 15 713 points
(-0.01%) $82.80
(0.73%) $1.665
(-0.45%) $2 327.90
(-0.59%) $27.19
(-0.40%) $912.10
(0.03%) $0.935
(0.14%) $11.00
(0.03%) $0.803
(-0.01%) $92.31
Quarter results tomorrow
(bmo 2024-04-25)
Expected move: +/- 1.97%
@ $46.69
Išleistas: 24 bal. 2024 @ 22:51
Grąža: -0.17%
Ankstesnis signalas: bal. 24 - 20:35
Ankstesnis signalas:
Grąža: -0.16 %
Live Chart Being Loaded With Signals
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 1.66M |
Vidutinė apimtis | 1.95M |
Rinkos kapitalizacija | 109.20B |
EPS | $0 ( 2024-02-01 ) |
Kita pelno data | ( $0.970 ) 2024-04-25 |
Last Dividend | $1.903 ( 2023-05-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 20.35 |
ATR14 | $1.020 (2.19%) |
Tūris Koreliacija
Sanofi American Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PPH | 0.936 |
PWOD | 0.93 |
ACAHU | 0.925 |
WLFC | 0.914 |
NWFL | 0.914 |
EVOP | 0.913 |
ROST | 0.91 |
SGHT | 0.909 |
HZNP | 0.907 |
MGI | 0.907 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
LNSR | -0.936 |
MEDS | -0.922 |
VS | -0.919 |
LHDX | -0.915 |
STRC | -0.912 |
TIL | -0.911 |
QLGN | -0.91 |
ULBI | -0.91 |
PLMR | -0.909 |
SG | -0.909 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Sanofi American Koreliacija - Valiuta/Žaliavos
Sanofi American Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $43.07B |
Bruto pelnas: | $26.50B (61.52 %) |
EPS: | $4.31 |
Q4 | 2023 |
Pajamos: | $22.88B |
Bruto pelnas: | $14.68B (64.16 %) |
EPS: | $1.570 |
Q3 | 2023 |
Pajamos: | $12.70B |
Bruto pelnas: | $8.86B (69.75 %) |
EPS: | $2.01 |
Q2 | 2023 |
Pajamos: | $10.68B |
Bruto pelnas: | $7.41B (69.41 %) |
EPS: | $2.74 |
Financial Reports:
No articles found.
Sanofi American Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$3.28 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.462 | 2003-05-28 |
Last Dividend | $1.903 | 2023-05-30 |
Next Dividend | $0 | N/A |
Payout Date | 2023-06-23 | |
Next Payout Date | N/A | |
# dividends | 24 | -- |
Total Paid Out | $33.25 | -- |
Avg. Dividend % Per Year | 3.34% | -- |
Score | 4.99 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 7.30 | |
Div. Directional Score | 9.72 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.462 | 1.49% |
2004 | $0.610 | 1.60% |
2005 | $0.799 | 2.01% |
2006 | $0.912 | 2.00% |
2007 | $1.145 | 2.48% |
2008 | $1.510 | 3.31% |
2009 | $1.419 | 4.34% |
2010 | $1.627 | 3.99% |
2011 | $1.822 | 5.55% |
2012 | $1.756 | 4.72% |
2013 | $1.862 | 3.89% |
2014 | $1.910 | 3.69% |
2015 | $1.618 | 3.55% |
2016 | $1.630 | 3.86% |
2017 | $1.577 | 3.84% |
2018 | $1.861 | 4.30% |
2019 | $1.739 | 4.06% |
2020 | $1.753 | 3.46% |
2021 | $1.906 | 3.91% |
2022 | $2.04 | 4.02% |
2023 | $3.28 | 6.69% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.139 | 1.500 | 7.23 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0627 | 1.200 | 7.91 | 9.49 | [0 - 0.3] |
returnOnEquityTTM | 0.108 | 1.500 | 9.92 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.579 | -1.000 | 4.21 | -4.21 | [0 - 1] |
currentRatioTTM | 1.267 | 0.800 | 8.66 | 6.93 | [1 - 3] |
quickRatioTTM | 0.827 | 0.800 | 9.84 | 7.87 | [0.8 - 2.5] |
cashRatioTTM | 0.360 | 1.500 | 9.11 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.132 | -1.500 | 7.80 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 9.29 | 1.000 | 7.67 | 7.67 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 7.20 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.225 | -1.500 | 9.10 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.678 | 1.000 | 2.03 | 2.03 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.260 | 1.000 | 6.80 | 6.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.615 | 1.000 | 7.69 | 7.69 | [0.2 - 2] |
assetTurnoverTTM | 0.452 | 0.800 | -0.322 | -0.258 | [0.5 - 2] |
Total Score | 12.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 14.12 | 1.000 | 8.67 | 0 | [1 - 100] |
returnOnEquityTTM | 0.108 | 2.50 | 9.95 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.60 | 2.00 | 8.13 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.98 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.20 | 2.00 | 7.27 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.579 | 1.500 | 4.21 | -4.21 | [0 - 1] |
pegRatioTTM | 0.645 | 1.500 | 9.03 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.180 | 1.000 | 8.01 | 0 | [0.1 - 0.5] |
Total Score | 7.30 |
Sanofi American
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.